AAV-EnSM22a-EGFP

AAV-EnSM22a-EGFP series viruses are ready to use AAV vectors carrying EnSM22a-EGFP expression cassette. The AAV-EnSM22a-EGFP vectors are available with 16 different serotypes, and there are over 1000 AAV serotypes/variants to be choose for custom AAV packaging.
The EnSM22a promoter is chimeric vascular smooth muscle-specific enhancer/promoter based on the SM22α (Smooth Muscle 22 alpha) promoter, a regulatory element that controls the expression of the SM22α gene. SM22α, also known as transgelin, is a protein predominantly expressed in smooth muscle cells and plays a key role in smooth muscle cell differentiation and function. This engineered promoter combines elements from natural smooth muscle-specific regulatory sequences, optimizing them for enhanced specificity and activity in vascular smooth muscle cells (VSMCs).
By employing EGFP as a reporter, researchers gain the ability to effortlessly visualize and quantify the transduction efficiency of AAV vectors within target cells, further enhancing the precision of their experiments.

Please contact us at for specific academic pricing.

Background

AAV viruses or AAV vectors, are a convenient solution for researchers who need to perform gene delivery experiments, such as gene therapy, gene editing, and gene regulation. The premade AAV viruses are available in various serotypes, promoters, and reporters/transgenes, allowing researchers to choose the most suitable vector for their specific research application. With over a thousand known AAV serotypes, customers have the tools to rapidly determine the vector specificity for various cell types. Additionally, the availability of multiple promoters paired with reporter genes allows for easy assessment and monitoring of gene expression levels and timing.

To ensure high-quality and pure products, various assays are used to assess the quality and purity of their AAV vectors:
· Gene specific qPCR Titer: Target the specific transgenes or common used elements, such as WPRE, CMV, PolyA, but not ITR.
· Full/Empty Particle Ratio: Ensure all the premade AAVs has >80% full particles by Mass Photometry.
· Endotoxin Testing: Ensure safety with endotoxin level <1U/1e13VG.
· SDS-PAGE Gel: Assess the purity of the AAV viruses is great than 95%.
· Infectivity Assay: Evaluate the efficiency of AAV viruses in transducing target cells if they have reporters.